ERBB2 and neoplasm: We have analysed the information from this database for two reasons: first, to ensure that our use of Trastuzumab and our outcome data are comparable to published results and NICE guidance; and second, to use this large data set in an attempt to demonstrate a benefit, if any, of adjuvant Trastuzumab in our HER2+ patients with node-negative T1a or T1b tumours.